JP2023531869A5 - - Google Patents
Info
- Publication number
- JP2023531869A5 JP2023531869A5 JP2022571216A JP2022571216A JP2023531869A5 JP 2023531869 A5 JP2023531869 A5 JP 2023531869A5 JP 2022571216 A JP2022571216 A JP 2022571216A JP 2022571216 A JP2022571216 A JP 2022571216A JP 2023531869 A5 JP2023531869 A5 JP 2023531869A5
- Authority
- JP
- Japan
- Prior art keywords
- tetramethyl
- oxo
- ions
- oxazaphosfinan
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2005138 | 2020-05-20 | ||
| FR2005138A FR3110393B1 (fr) | 2020-05-20 | 2020-05-20 | Compose et composition pour induire une neuroprotection |
| PCT/FR2021/050929 WO2021234324A1 (fr) | 2020-05-20 | 2021-05-20 | Compose et composition pour induire une neuroprotection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531869A JP2023531869A (ja) | 2023-07-26 |
| JP2023531869A5 true JP2023531869A5 (https=) | 2024-05-27 |
Family
ID=73013493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571216A Pending JP2023531869A (ja) | 2020-05-20 | 2021-05-20 | 神経保護を誘導するための化合物及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12611387B2 (https=) |
| EP (1) | EP4142703B8 (https=) |
| JP (1) | JP2023531869A (https=) |
| KR (1) | KR20230013116A (https=) |
| CN (1) | CN116981449A (https=) |
| CA (1) | CA3178633A1 (https=) |
| ES (1) | ES2970378T3 (https=) |
| FR (1) | FR3110393B1 (https=) |
| WO (1) | WO2021234324A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3149773B1 (fr) | 2023-06-19 | 2026-04-17 | Rest Therapeutics | Nouvelles combinaisons synergiques a base de fenm |
| WO2026003229A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament |
| FR3163834A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine |
| FR3163835A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200418446A (en) * | 2002-10-24 | 2004-10-01 | Merz Pharma Gmbh & Co Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| MX2007004491A (es) * | 2004-10-15 | 2007-08-08 | Johnson & Johnson | Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos. |
| US20090118376A1 (en) * | 2007-11-02 | 2009-05-07 | Ru-Band Lu | Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia |
| FR2935611B1 (fr) | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| US20120115943A1 (en) * | 2008-10-01 | 2012-05-10 | National Taiwan University | Composition and method for neuroprotection against excitotoxic injury |
| EP2586436A1 (en) * | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
| FR3006193B1 (fr) | 2013-05-29 | 2015-06-19 | Holis Technologies | Nouveaux composes chimiques derives de la memantine et susceptibles de se fixer sur les recepteurs de n-methyl-d-aspartate (nmda) |
| FR3050732B1 (fr) | 2016-05-02 | 2019-06-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques |
| FR3075038B1 (fr) | 2017-12-15 | 2020-03-06 | Melchior Material And Life Science France | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
| EP3968977A4 (en) * | 2019-05-15 | 2023-01-11 | The Trustees of Columbia University in the City of New York | COMPOSITIONS AND METHODS AGAINST STRESS-INDUCED MOOD DISORDERS AND THEIR ASSOCIATED SYMPTOMS |
-
2020
- 2020-05-20 FR FR2005138A patent/FR3110393B1/fr active Active
-
2021
- 2021-05-20 CN CN202180060125.1A patent/CN116981449A/zh active Pending
- 2021-05-20 ES ES21734182T patent/ES2970378T3/es active Active
- 2021-05-20 WO PCT/FR2021/050929 patent/WO2021234324A1/fr not_active Ceased
- 2021-05-20 US US17/924,420 patent/US12611387B2/en active Active
- 2021-05-20 EP EP21734182.5A patent/EP4142703B8/fr active Active
- 2021-05-20 CA CA3178633A patent/CA3178633A1/fr active Pending
- 2021-05-20 JP JP2022571216A patent/JP2023531869A/ja active Pending
- 2021-05-20 KR KR1020227044712A patent/KR20230013116A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531869A5 (https=) | ||
| RU2368604C2 (ru) | Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина | |
| EP2813498B1 (en) | Compounds for Alzheimer's disease | |
| JP2006504656A5 (https=) | ||
| US9034871B2 (en) | Compounds for Alzheimer's disease | |
| US20120225845A1 (en) | Compounds for diseases and disorders | |
| JP2005506308A5 (https=) | ||
| US20080188524A1 (en) | Methods of treating pain | |
| AU2007214128B2 (en) | Use of KCNQ-openers for treating or reducing the symptoms of schizophrenia | |
| US20220008414A1 (en) | Pharmaceutical composition comprising histone deacetylase 6 inhibitors | |
| EP1641461B1 (fr) | Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes | |
| JP7398831B2 (ja) | 神経変性疾患の予防及び／又は治療剤 | |
| JP7309824B2 (ja) | 不安障害を治療するための（２Ｓ）－１－［４－（３，４－ジクロロフェニル）ピペリジン－１－イル］－３－［２－（５－メチル－１，３，４－オキサジアゾール－２－イル）ベンゾ［ｂ］フラン－４－イルオキシ］プロパン－２－オールまたはその代謝産物 | |
| KR930006009A (ko) | 4-[4-[4-(4-히드록시페닐)-1-피페라지닐]페닐]-5-메틸-3h-1,2,4-트리아졸-3-온 유도체 | |
| US7470708B2 (en) | Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies | |
| JP6025886B2 (ja) | 慢性疼痛治療剤 | |
| HRP20241657T1 (hr) | Supstituirani derivat tetrahidroizokinolina kao d1 pozitivni alosterički modulator | |
| CN116963736A (zh) | 马赛替尼用于治疗阿尔茨海默病 | |
| KR101503782B1 (ko) | 신경 세포사 억제제 | |
| TW201208683A (en) | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies | |
| JPH11335286A (ja) | ドーパミン拮抗薬の効果増強剤 | |
| JP2008516898A5 (https=) | ||
| HK1129593A1 (en) | Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia | |
| KR20200099153A (ko) | 외상 후 증후군 장애의 치료 | |
| HK1129593B (en) | Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia |